FATE THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
FATE$1.94+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
EXHIBIT INDEX
| Incorporated byReference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Title | Form | File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | S-1/A | 333-190608 | 3.2 | August 29, 2013 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect | 8-K | 001-36076 | 3.1 | June 7, 2021 |
| 3.3 | Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock | 8-K | 001-36076 | 3.1 | November 29, 2016 |
| 3.4 | Amended and Restated Bylaws of the Registrant, as currently in effect | 10-K | 001-36076 | 3.3 | February 24, 2021 |
| 3.5 | Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Class A Convertible Preferred Stock of the Registrant | 8-K | 001-36076 | 3.1 | April 19, 2023 |
| 3.6 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect | 8-K | 001-36076 | 3.1 | June 10, 2024 |
| 4.1 | Specimen Common Stock Certificate | S-1/A | 333-190608 | 4.1 | August 29, 2013 |
| 4.2 | Form of Pre-Funded Warrant | 8-K | 001-36076 | 4.1 | January 8, 2021 |
| 4.3 | Form of Pre-Funded Warrant | 8-K | 001-36076 | 4.1 | March 21, 2024 |
| 4.4 | Description of Securities | 10-Q | 001-36076 | 4.3 | November 8, 2023 |
| 10.1# | Amended and Restated 2013 Stock Option and Incentive Plan and forms of agreements thereunder | 10-K | 001-36076 | 10.2 | February 24, 2021 |
| 10.2# | Form of Unrestricted Stock Award Agreement under the 2013 Stock Option and Incentive Plan | 8-K | 001-36076 | 10.2 | January 7, 2015 |
| 10.3# | Amended and Restated Employment Agreement by and between the Registrant and Scott Wolchko, dated January 14, 2018 | 10-K | 001-36076 | 10.5 | March 5, 2018 |
| 10.4# | Amended and Restated Senior Executive Incentive Bonus Plan | 8-K | 001-36076 | 10.1 | January 7, 2015 |
| 10.5# | Amended and Restated Non-Employee Director Compensation Policy | — | — | — | Filed herewith |
| 10.6# | Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan | 10-K | 001-36076 | 10.8 | February 24, 2021 |
| 10.7# | Forms of Stock Option Agreement under the Registrant's Inducement Equity Plan | 10-K | 001-36076 | 10.9 | February 24, 2021 |
| 10.8# | Forms of Restricted Stock Unit Award Agreement under the Registrant's Inducement Equity Plan | 10-K | 001-36076 | 10.10 | February 24, 2021 |
| 10.9 | Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, LLC, dated December 3, 2009 | S-1 | 333-190608 | 10.14 | August 13, 2013 |
| 10.10 | First Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, LLC, dated October 1, 2011 | S-1 | 333-190608 | 10.15 | August 13, 2013 |
| 10.11 | Second Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated September 26, 2013 | S-1/A | 333-190608 | 10.25 | September 30, 2013 |
| 10.12 | Third Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated September 2, 2014 | 10-K | 001-36076 | 10.15 | March 3, 2016 |
| 10.13 | Fourth Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated March 2, 2015 | 10-K | 001-36076 | 10.16 | March 3, 2016 |
| 10.14 | Fifth Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated June 1, 2016 | 10-Q | 001-36076 | 10.2 | August 8, 2016 |
| 10.15† | Whitehead Institute for Biomedical Research Exclusive Patent License Agreement between the Registrant and the Whitehead Institute for Biomedical Research, dated as of February 24, 2009 | 10-K | 001-36076 | 10.19 | February 24, 2021 |
| 10.16† | License Agreement between the Registrant and The Scripps Research Institute, dated as of July 13, 2009 | 10-K | 001-36076 | 10.20 | February 24, 2021 |
| 10.17† | License Agreement between the Registrant and The Scripps Research Institute, dated as of May 25, 2010 | 10-K | 001-36076 | 10.21 | February 24, 2021 |
| 10.18† | License Agreement between the Registrant and The Scripps Research Institute, dated as of August 24, 2010 | 10-K | 001-36076 | 10.22 | February 24, 2021 |
| 10.19# | Severance and Change in Control Policy | 10-K | 001-36076 | 10.32 | March 5, 2018 |
| 10.20# | Offer Letter by and between the Registrant and Cindy R. Tahl, dated October 23, 2009 | 10-K | 001-36076 | 10.33 | March 5, 2019 |
| 10.21 | Sixth Amendment to the Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated May 31, 2018 | 10-Q | 001-36076 | 10.1 | August 6, 2018 |
| 10.22 | Amended and Restated Exclusive License Agreement by and between the Registrant and Memorial Sloan Kettering Cancer Center, dated May 15, 2018 | 10-Q | 001-36076 | 10.2 | August 6, 2018 |
| 10.23† | Exclusive License Agreement by and between the Registrant and The David Gladstone Institutes, dated September 11, 2018 | 10-Q | 001-36076 | 10.1 | November 1, 2018 |
| 10.24† | Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd., dated September 14, 2018 | 10-Q/A | 001-36076 | 10.2 | February 8, 2019 |
| 10.25# | Offer Letter by and between the Registrant and Bahram Valamehr, dated November 23, 2009 | 10-K | 001-36076 | 10.38 | March 5, 2019 |
| 10.26† | Lease Agreement by and between the Registrant and Scripps Summit Investments LLC, dated January 7, 2020 | 10-K | 001-36076 | 10.34 | March 2, 2020 |
| 10.27† | Letter Agreement, dated December 4, 2020, by and between the Registrant and Ono Pharmaceutical Co., Ltd. | 10-K | 001-36076 | 10.39 | February 24, 2021 |
| 10.28† | Patent License Agreement by and between the Registrant and Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, dated August 30, 2019 | 10-K | 001-36076 | 10.40 | February 24, 2021 |
| 10.29 | Open Market Sale AgreementSM, dated November 8, 2023, by and between the Registrant and Jefferies LLC | S-3 | 333-275402 | 1.2 | November 8, 2023 |
| 10.30† | License Agreement, dated April 9, 2020, by and between the Registrant and Dana-Farber Cancer Institute, Inc. | 10-K | 001-36076 | 10.40 | February 28, 2022 |
| 10.31# | 2022 Stock Option and Incentive Plan and form agreements thereunder | S-8 | 333-265502 | 99.1 | June 9, 2022 |
| 10.32† | Amendment 01 to Collaboration and Option Agreement, dated June 28, 2022, by and between the Registrant and Ono Pharmaceutical Co. Ltd. | 10-Q | 001-36076 | 10.2 | August 3, 2022 |
| 10.33 | Letter Agreement, dated November 7, 2022, by and between the Registrant and Ono Pharmaceutical Co., Ltd. | 8-K | 001-36076 | 10.1 | November 7, 2022 |
| 10.34 | Amendment 03 to Collaboration and Option Agreement, dated November 30, 2023, by and between the Registrant and Ono Pharmaceutical Co. Ltd. | 10-K | 001-36076 | 10.41 | February 26, 2024 |
| 10.35† | Exclusive License Agreement, dated April 17, 2020, by and between the Registrant and Baylor College of Medicine | 10-K | 001-36076 | 10.42 | February 26, 2024 |
| 10.36 | Securities Purchase Agreement, dated March 19, 2024, between the Registrant and RedCo II Master Fund, L.P. | 8-K | 001-36076 | 10.1 | March 21, 2024 |
| 10.37# | Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder | 8-K | 001-36076 | 10.1 | June 7, 2024 |
| 10.38 | Amended and Restated Form of Indemnification Agreement | 8-K | 001-36076 | 10.1 | August 30, 2024 |
| 10.39† | Amendment No.4 to Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd, dated August 28, 2024 | 10-Q | 001-36076 | 10.2 | November 12, 2024 |
| 10.40# | Strategic Advisory Services Agreement between the Registrant and J. Scott Wolchko, dated as of December 31, 2024 | 8-K | 001-36076 | 10.1 | January 6, 2025 |
| 10.41# | Employment Agreement by and between the Registrant and Bahram Valamehr, dated March 3, 2025 | — | — | — | Filed herewith |
| 14.1 | Amended Code of Business Conduct and Ethics | 10-K | 001-36076 | 14.1 | February 26, 2024 |
| 19.1 | Insider Trading Policy | — | — | — | Filed herewith |
| 21.1 | Subsidiaries of the Registrant | 10-K | 001-36076 | 21.1 | February 28, 2023 |
| 23.1 | Consent of Independent Registered Public Accounting Firm | — | — | — | Filed herewith |
| 31.1 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14 and 15-d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 97.1 | Compensation Recovery Policy | 10-K | 001-36076 | 97.1 | February 26, 2024 |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | — | — | — | Filed herewith |
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document | — | — | — | Filed herewith |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). | — | — | — | Filed herewith |
† Certain provisions of this Exhibit have been omitted as confidential information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.